A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01023724|
Recruitment Status : Completed
First Posted : December 2, 2009
Results First Posted : August 26, 2011
Last Update Posted : August 26, 2011
|Condition or disease||Intervention/treatment||Phase|
|Post Operative Anterior Chamber Inflammation (Flare)||Drug: Ketorolac Tromethamine 0.45% Drug: Bromfenac 0.09%||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% BID and Bromfenac 0.09% BID|
|Study Start Date :||December 2009|
|Actual Primary Completion Date :||January 2010|
|Actual Study Completion Date :||February 2010|
Active Comparator: bromfenac 0.09%
bromfenac 0.09% drops to be given pre operatively for one day BID, and then postoperatively for 14 days.
Drug: Bromfenac 0.09%
Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
Active Comparator: Acuvail
Acuvail to be given preoperatively at BID for one day pre op and then post operatively for 14 days.
Drug: Ketorolac Tromethamine 0.45%
Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
- Anterior Chamber Inflammation (Flare) [ Time Frame: Day 14 of treatment ]Anterior chamber flare measured by assessing the number of inflammatory cells in the anterior chamber.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01023724
|United States, Pennsylvania|
|Bucci Laser Vision Institute|
|Wilkes-Barre, Pennsylvania, United States, 18702|
|Principal Investigator:||Frank A Bucci, Jr., MD||Bucci Laser Vision Institute|